BioSpace News Archive

L7 Informatics announced that it has partnered with Cognate BioServices, Inc., the premier commercial-ready CDMO in the Cell & Gene Therapy industry, to deploy L7|ESP (Enterprise Science Platform) and implement an integrated manufacturing and lab system. Specifically, L7 will provide Cognate BioServices with a unified data and

Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operating Expenses to Align with Streamlined Development Programs Discontinues Development of Apulmiq Program, Focuses Resources on Molgradex in aPAP

Heat Biologics, Inc. today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-7. The reverse stock split will take effect as of 12:01 a.m. ET, December 11, 2020.

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor’s BVA-100® Blood Volume Analyzer at major medical centers across the U.S.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS)

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that on Wednesday, December 16, 2020, at 1:00 Eastern time,

Viveve authorized to increase trial size and introduce new patient selection criteria designed to improve studys power and data to support assessment of primary efficacy endpoint Near-term launch planned for pivotal U.S. PURSUIT trial

Agendia, Inc., a world leader in precision oncology for breast cancer, today announced data from the APHINITY trial in a poster spotlight discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).

BioSkryb’s grant program will support up to two researchers to empower their discoveries through ResolveDNA™, the company’s novel whole genome amplification products that provide unprecedented genome coverage and accuracy ResolveDNA incorporates BioSkryb’s primary template-directed amplification (PTA) technology, which was created to address the inherent challenges of single-cell genomics by producing high-quality gene sequencing data DURHAM,

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announced that the Company’s T-Cell Select reagent kit has been approved for use by the Ministry of Food and Drug Safety, South Korea. The T-Cell Select reagent kit is an immune cell separation reagent. It is used to automate the preparation of the cells required to run the Company’s T-SPOT. TB test,